Blueprint Medicines所有资讯

Blueprint Medicines | 8-K：Blueprint Medicinib 公布了强劲的2024年第一季度业绩，并上调了AYVAKIT® /AYVAKYT®（avapritinib）全年收入指引

57分钟前

Blueprint Medicines | ARS：年度报告

04/26 05:31

Blueprint Medicines | DEF 14A：股东委托书决议

04/26 05:26

Blueprint Medicines | 8-K：重大事件

04/25 20:35

Blueprint Medicines | SC 13G/A：超过5%持股股东披露文件(修正)-T. ROWE PRICE ASSOCIATES, INC.(10.2%)

04/11 01:02

Blueprint Medicines | 4：持股变动声明-高管 Landsittel Michael

04/02 04:42

Blueprint Medicines | 144：拟议出售证券

03/29 06:00

Blueprint Medicines | 4：持股变动声明-董事 Albers Jeffrey W.

03/27 09:15

Blueprint Medicines | 4：持股变动声明-董事 Albers Jeffrey W.

03/23 05:53

Blueprint Medicines | 4：持股变动声明-高管 Landsittel Michael

03/20 05:13

Blueprint Medicines | 4：持股变动声明-高管 Hurley Ariel

03/20 04:54

Blueprint Medicines | 144：拟议出售证券

03/16 05:27

Blueprint Medicines | 144：拟议出售证券

03/16 04:52

Blueprint Medicines | 4：持股变动声明-高管 Lee Philina

03/16 04:52

Blueprint Medicines | 144：拟议出售证券

03/14 04:24

Blueprint Medicines | 4：持股变动声明-高管 Hewes L. Becker

03/12 06:33

Blueprint Medicines | 4：持股变动声明-高管 Durso-Bumpus Debra

03/12 06:33

Blueprint Medicines | 4：持股变动声明-高管 Haviland Kate

03/12 06:28

Blueprint Medicines | 4：持股变动声明-高管 Lee Philina

03/12 06:28

Blueprint Medicines | 4：持股变动声明-高管 Murray Christopher K.

03/12 06:28